A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema

PHASE1CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

July 22, 2019

Primary Completion Date

November 13, 2023

Study Completion Date

November 13, 2023

Conditions
Diabetic Macular EdemaUveitic Macular Edema
Interventions
DRUG

RO7200220

RO7200220 was administered as IVT injection.

DRUG

Ranibizumab

Ranibizumab was administered as IVT injection.

Trial Locations (19)

19107

Mid Atlantic Retina, Philadelphia

21740

Cumberland Valley Retina PC, Hagerstown

22903

Univ of Virginia Ophthalmology, Charlottesville

27157

Wake Forest Baptist Medical Center, Winston-Salem

32901

Florida Eye Associates, Melbourne

33711

Retina Vitreous Assoc of FL, St. Petersburg

44195

Cleveland Clinic Foundation, Cleveland

60304

Illinois Retina Associates SC, Oak Park

78240

Medical Center Ophthalmology Associates, San Antonio

78503

Valley Retina Institute P.A., McAllen

78750

Austin Clinical Research LLC, Austin

79606

Retina Res Institute of Texas, Abilene

89502

Sierra Eye Associates, Reno

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

92260

Retina Institute of California Medical Group d/b/a Acuity Eye Group, Palm Desert

93036

California Retina Consultants, Oxnard

94303

Byers Eye Insitute at Stanford, Palo Alto

97239

Oregon HSU, Portland

98109

Karalis Johnson Retina Center, Seattle

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06771271 - A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema | Biotech Hunter | Biotech Hunter